Robin E Pearce

Summary

Affiliation: Children's Mercy Hospital
Country: USA

Publications

  1. ncbi request reprint Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene
    Robin E Pearce
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, Missouri 64108, USA
    Drug Metab Dispos 33:1819-26. 2005
  2. pmc The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst
    Robin E Pearce
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Clinical Pharmacology and Therapeutic Innovation, The Children s Mercy Hospitals, Kansas City, MO 64108, USA
    Drug Metab Dispos 41:1686-94. 2013
  3. ncbi request reprint Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms
    R E Pearce
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospital, Kansas City, Missouri 64108, USA
    Drug Metab Dispos 29:1548-54. 2001
  4. ncbi request reprint Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites
    Robin E Pearce
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, Missouri 64108, USA
    Drug Metab Dispos 30:1170-9. 2002
  5. pmc Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine
    Robin E Pearce
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    Drug Metab Dispos 36:1637-49. 2008
  6. ncbi request reprint Variability of CYP3A7 expression in human fetal liver
    J Steven Leeder
    Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    J Pharmacol Exp Ther 314:626-35. 2005
  7. doi request reprint Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype
    J Steven Leeder
    Section of Developmental Pharmacology and Experimental Therapeutics, Department of Pediatrics, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    J Clin Pharmacol 48:1041-51. 2008
  8. pmc Variability of CYP2J2 expression in human fetal tissues
    Andrea Gaedigk
    Children s Mercy Hospital, Division of Clinical Pharmacology, 2401 Gillham Rd, Kansas City, MO 64108, USA
    J Pharmacol Exp Ther 319:523-32. 2006
  9. ncbi request reprint Biotransformation of fluticasone: in vitro characterization
    Robin E Pearce
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Department of Pediatrics, Children s Mercy Hospitals and Clinics, Kansas City, MO 64108, USA
    Drug Metab Dispos 34:1035-40. 2006
  10. ncbi request reprint Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants
    Michael J Blake
    Department of Pediatrics, University of Missouri Kansas City, School of Medicine and the Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, Missouri 64108, USA
    Pediatr Res 60:717-23. 2006

Detail Information

Publications18

  1. ncbi request reprint Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene
    Robin E Pearce
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, Missouri 64108, USA
    Drug Metab Dispos 33:1819-26. 2005
    ....
  2. pmc The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst
    Robin E Pearce
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Clinical Pharmacology and Therapeutic Innovation, The Children s Mercy Hospitals, Kansas City, MO 64108, USA
    Drug Metab Dispos 41:1686-94. 2013
    ..These results suggest that CYP2A6 is the primary catalyst responsible for the 2-hydroxylation of metronidazole, a reaction that may function as a marker of CYP2A6 activity both in vitro and in vivo...
  3. ncbi request reprint Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms
    R E Pearce
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospital, Kansas City, Missouri 64108, USA
    Drug Metab Dispos 29:1548-54. 2001
    ..g., ontogeny of drug-metabolizing enzymes, inhibition, and induction) should be clinically unimportant due to the apparent lack of dependence on cytochromes P450 for elimination...
  4. ncbi request reprint Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites
    Robin E Pearce
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, Missouri 64108, USA
    Drug Metab Dispos 30:1170-9. 2002
    ..These results suggest that CYP2B6 and CYP3A4 are largely responsible for the formation of 3-hyrdoxycarbamazepine, whereas multiple P450s (CYP1A2, 2A6, 2B6, 2E1, and 3A4) contributed to 2-hydroxycarbamazepine formation...
  5. pmc Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine
    Robin E Pearce
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    Drug Metab Dispos 36:1637-49. 2008
    ....
  6. ncbi request reprint Variability of CYP3A7 expression in human fetal liver
    J Steven Leeder
    Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    J Pharmacol Exp Ther 314:626-35. 2005
    ..2-fold (8.07 +/- 2.87, range 2.41 to 14.9 nmol/min/mg). Observed variability in CYP3A7 activity was not related to CYP3A7*2, and alternative regulatory mechanisms require further investigation...
  7. doi request reprint Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype
    J Steven Leeder
    Section of Developmental Pharmacology and Experimental Therapeutics, Department of Pediatrics, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    J Clin Pharmacol 48:1041-51. 2008
    ..Although further development is required, these studies suggest that the [(13)C]-DM breath test offers promise as a rapid, minimally invasive phenotyping assay for CYP2D6 activity...
  8. pmc Variability of CYP2J2 expression in human fetal tissues
    Andrea Gaedigk
    Children s Mercy Hospital, Division of Clinical Pharmacology, 2401 Gillham Rd, Kansas City, MO 64108, USA
    J Pharmacol Exp Ther 319:523-32. 2006
    ..Due to premature termination codons, none encodes functional protein. The mechanisms leading to variable amounts of immunoreactive protein and distinct pre- and postnatal CYP2J2 protein patterns warrant further investigation...
  9. ncbi request reprint Biotransformation of fluticasone: in vitro characterization
    Robin E Pearce
    Division of Pediatric Clinical Pharmacology and Medical Toxicology, Department of Pediatrics, Children s Mercy Hospitals and Clinics, Kansas City, MO 64108, USA
    Drug Metab Dispos 34:1035-40. 2006
    ..These results suggest that at pharmacologically relevant concentrations, biotransformation of FTP to M1 is mediated predominantly by CYP3A enzymes in the liver...
  10. ncbi request reprint Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants
    Michael J Blake
    Department of Pediatrics, University of Missouri Kansas City, School of Medicine and the Division of Pediatric Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, Missouri 64108, USA
    Pediatr Res 60:717-23. 2006
    ..Dietary modification of CYP activity may modulate drug biotransformation and thus alter systemic exposure to xenobiotics from a very early age...
  11. doi request reprint Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations
    Andrea Gaedigk
    Division of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
    Eur J Clin Pharmacol 66:859-64. 2010
    ..We aimed to resolve the CYP2D6 31 no-calls, determine the allele haplotype, and corroborate that CYP2D6 31 is associated with a poor metabolizer phenotype...
  12. ncbi request reprint Ontogeny of dextromethorphan O- and N-demethylation in the first year of life
    M J Blake
    Division of Pediatric Pharmacology and Medical Toxicology, Department of Pediatrics, Children s Mercy Hospitals and Clinics, Kansas City, Missouri, USA
    Clin Pharmacol Ther 81:510-6. 2007
    ..In contrast, DM N-demethylation developed significantly more slowly over the first year of life. Genotype and the temporal acquisition of drug biotransformation are critical determinants of a drug response in infants...
  13. ncbi request reprint The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype
    A Gaedigk
    Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, Kansas City, Missouri, USA
    Clin Pharmacol Ther 83:234-42. 2008
    ..The AS tool warrants further prospective evaluation for CYP2D6 substrates and in additional ethnic populations...
  14. ncbi request reprint Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype
    A Gaedigk
    Section of Developmental Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, Kansas City, Missouri, USA
    Clin Pharmacol Ther 81:817-20. 2007
    ..The rationale for this study was to resolve the discordance and to describe the novel non-functional allelic variant of CYP2D6 and its frequency in populations of different ethnic backgrounds...
  15. pmc Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans
    A Gaedigk
    Division of Clinical Pharmacology and Experimental Therapeutics, Children s Mercy Hospital and Clinics, Kansas City, MO 64108, USA
    Pharmacogenomics J 5:173-82. 2005
    ..CYP2D6(*)45 and (*)46 have a combined frequency of 4% and can be identified by a common SNP. Carriers are predicted to exhibit an extensive or intermediate CYP2D6 phenotype...
  16. ncbi request reprint Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine
    Kenda A Marcucci
    Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Clinical Pharmacology and Toxicology, Children s Mercy Hospital and Clinics, Kansas City, Missouri 64108, USA
    Drug Metab Dispos 30:595-601. 2002
    ..1. These data indicate that CYP2D6.17 exhibits reduced metabolic activity toward all three commonly used CYP2D6 substrates, although specific effects on substrate affinity and turnover demonstrate some substrate dependence...
  17. doi request reprint Urinary biomarkers of trimethoprim bioactivation in vivo following therapeutic dosing in children
    Leon van Haandel
    Division of Clinical Pharmacology and Therapeutic Innovation, Children s Mercy Hospitals and Clinics, and Department of Pediatrics, School of Medicine, University of Missouri Kansas City, 2401 Gillham Road, Kansas City, Missouri 64108, United States
    Chem Res Toxicol 27:211-8. 2014
    ..As a result, the TMP component of TMP-SMX should be considered as well when evaluating adverse drug reactions to TMP-SMX. ..
  18. pmc CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile
    Ping Kang
    Department of Cellular and Molecular Pharmacology, Liver Center, University of California, San Francisco, 600 16th Street N572F, San Francisco, CA 94158 2280, USA
    Drug Metab Dispos 36:490-9. 2008
    ....